Analysis results of combined treatment of patients with verified cancer of the cervical esophagus and hypopharynx with the application of surgical treatment with one-stage defect’s plastic

In the treatment of many unresolved issues, indicating the need for research aimed at finding more effective treatment approaches. The aim of the study is to analyze the results of combined treatment of patients with widespread forms of cancer of the cervical esophagus and hypopharynx with the application of surgical treatment in the amount of pharyngolaryngitis with single-step plastic of the defect. A retrospective analysis of results of combined treatment of 28 patients with a verified diagnosis of cancer of the cervical esophagus and hypopharynx. Combined treatment of patients with cancer of the cervical esophagus and hypopharynx included the following treatments: induction chemoradiotherapy according to the scheme cisplatin/5-fluorouracil, external beam radiation therapy 65 Gy, brachytherapy (7 Gy 1 time per week, 3 sessions), surgical treatment with one-stage plastic of the esophagus. In 7 patients (25 %) was achieved complete regression on the background of induction chemo-therapy, 21 patients (75 %) received the treatment in full. Postoperative mortality rate was of 9.52 %, post-operative complications such as anastomosis dehiscence – 19 %. 

1. Malaisrie S.C., Untch B., Aranha G.V. et al. Neoadjuvant chemoradiotherapy for locally advanced esophageal cancer: experience at a single institution. Arch Surg 2004;139(5):532–8.

2. Mattioli F., Bettini M., Molteni G. et al. Analysis of risk factors for pharingocutaneus fistula after total laryngectomy with particular focus on nutritional status. Acta Otorhinolaryngol Ital 2015;35(4):243–8.

3. NCCN Clinical Practice Guidelines in Oncology. Esophageal and esophagogastric junction cancers. Version 2. 2016. P. 97.

4. Schwer A.L., Ballonoff A., McCammon R.J. et al. Survival effect of neoadjuvant radiotherapy before esophagectomy for patients with esophageal cancer: a surveillance, epidemiology, and end-results study. Int J Radiant Oncol Biol Phys 2009;73(2):449–55.

5. Давыдов М.И., Стилиди И.С. Рак пищевода. М.: Практическая медицина, 2007. С. 20–25. [Davydov M.I., Stilidi I.S. Esophageal cancer. M.: Practical Medicine, 2007. Pp. 20–25. (In Russ.)].

6. Мерабишвили В.М. Выживаемость онкологических больных. Вып. 2. Ч. 1. СПб., 2011. [Merabishvili V.M. Survival of oncologic patients. Issue 2. Part 1. Saint-Peterburg, 2011. (In Russ.)].

7. Минимальные клинические рекомендации Европейского общества медицинской онкологии (ESMO). Ред. рус. пер.: С.А. Тюляндин, Н.И. Переводчикова, Д.А. Носов. М.: Издательская группа РОНЦ им. Н.Н. Блохина РАМН, 2010. 436 с. [Minimum Clinical Recommendations of the European Society for Medical Oncology (ESMO). Editors of Russian translation: S.A. Tylyandin, N.I. Perevodchikova, D.A. Nosov. M.: Publishing group of N.N. Blokhin Russian Cancer Research Center of RAMS, 2010. 436 p. (In Russ.)].

8. Чиссов В.И., Старинский В.В., Петрова Г.В. Злокачественные новообразования в России в 2008 году (заболеваемость и смертность). М.: МНИОИ им. П.А. Герцена, 2010. 256 с. [Chissov V.I., Starinsky V.V., Petrova G.V. Malignant neoplasms in Russia in 2008 (morbidity and mortality). M.: P.A. Herzen Moscow Research Institute of Oncology, 2010. 256 p. (In Russ.)].